EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment

Last updated: 16.7.2025
Hybrid

The EIC Accelerator Challenge: Novel biomarker-based assays to guide personalised cancer treatment supports innovative European SMEs and small mid-caps in developing groundbreaking diagnostic tools for precision oncology. This program provides blended finance, combining grants and equity investments, to accelerate preclinical validation and early clinical development, ultimately aiming to transform cancer care through personalised treatment strategies.

Who is Funded

This section details the eligibility criteria for applicants, the geographical areas covered by the program, and its core objectives. The funding primarily targets innovative businesses within EU Member States and Associated Countries, focusing on advancements in cancer diagnostics and personalised treatment.

What is Funded

This section outlines the types of projects and thematic areas eligible for funding, focusing on innovative diagnostic solutions for cancer. It also clarifies the typical development stages for supported projects.

Type and Scope of Funding

This section provides details on the financial support offered, including the type of instruments used, the funding amounts available, and the typical project durations.

Conditions and Requirements

This section outlines the key rules and specific requirements for applicants and beneficiaries, covering application terms, submission limitations, and adherence to relevant financial and policy provisions.

Application Procedure

This section outlines the multi-stage application process for the EIC Accelerator Challenge, from initial submission to evaluation, and how funding decisions are reached.

This section outlines the foundational legal and official documents that govern the EIC Accelerator Challenge, ensuring its legitimacy and guiding its operational framework.

Similar Programs

#EIC Accelerator#cancer treatment#biomarker assays#personalised medicine#precision oncology#SME funding#Horizon Europe#medical technology innovation#diagnostic tools#EU grants#equity investment#preclinical validation#clinical trials#European innovation#healthcare research#biotech funding

Funding Overview

Funding Status

Funding Status:

Closed

Maximum Amount

Maximum Amount:

17,500,000 €

Allocated Budget

Allocated Budget:

1,135,239,839 € for 2023 (for EIC Accelerator Blended Finance calls)

Award Channel

Award Channel:

Framework Programme Call

Region

Region:

EU Member States and Associated Countries. Applicants from the United Kingdom can apply, but only for grant-only funding, subject to the positive conclusion of association negotiations.

Sectors

Sectors:

Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development

Beneficiaries

Beneficiaries:

Healthcare

Application Type

Application Type:

Single Applicant

Funding Stages

Funding Stages:

Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development

Funding Provider

Program Level:

European Union

Funding Body:

European Commission (Horizon Europe)

Managed By:

European Innovation Council (EIC) / EIC Fund

0 x 0
XS